ID: MRFR/HC/7013-HCR | 111 Pages | Author: Kinjoll Dey | March 2024
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE
6.1. Overview
6.2. Diabetic Peripheral Neuropathy (DPN)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.4. Idiopathic Peripheral Neuropathy
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.5. HIV/AIDS Associated Peripheral Neuropathy
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT
7.1. Overview
7.2. Pharmacological Therapies
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.1. Pain Relievers
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.2. Anti-seizure Medications
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.2.3. Antidepressants
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3. Non-Pharmacological Therapies
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.1. Transcutaneous Electrical Nerve Stimulation
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3.2. Plasma Exchange and Intravenous Immune Globulin
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4. Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.3. Ambulatory Settings
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.4. Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1.1. Overview
10.1.2. Competitive Analysis
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Type Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Bristol Myers Squibb
11.2.1. Company Overview
11.2.2. Product Type Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Novartis
11.3.1. Company Overview
11.3.2. Product Type Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Product Type Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Pfizer Inc
11.5.1. Company Overview
11.5.2. Product Type Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. GlaxoSmithKline plc
11.6.1. Company Overview
11.6.2. Product Type Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Merck and Co. Inc.
11.7.1. Company Overview
11.7.2. Product Type Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Cipla Limited
11.8.1. Company Overview
11.8.2. Product Type Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Lupin Limited
11.9.1. Company Overview
11.9.2. Product Type Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Dr. Reddy's Laboratories
11.10.1. Company Overview
11.10.2. Product Type Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. F. Hoffmann-La Roche Ltd.
11.11.1. Company Overview
11.11.2. Product Type Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. RxFunction, Inc.
11.12.1. Company Overview
11.12.2. Product Type Overview
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SYNOPSIS, 2023-2030
TABLE 2 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET ESTIMATES & FORECAST, 2023-2030 (USD MILLION)
TABLE 3 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 4 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 5 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 6 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 9 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 10 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 11 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 12 US: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 13 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 14 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 15 CANADA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 16 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 17 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, TREATMENT, 2023-2030 (USD MILLION)
TABLE 18 LATIN AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 19 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 20 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 21 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 22 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 23 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 24 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 25 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 26 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 27 EASTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET
FIGURE 4 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY TYPE, 2020 (%)
FIGURE 5 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)
FIGURE 6 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABBOTT LABORATORIES: KEY FINANCIALS
FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE
FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE
FIGURE 17 BRISTOL MYERS SQUIBB: KEY FINANCIALS
FIGURE 18 BRISTOL MYERS SQUIBB: SEGMENTAL REVENUE
FIGURE 19 BRISTOL MYERS SQUIBB: REGIONAL REVENUE
FIGURE 20 NOVARTIS AG: KEY FINANCIALS
FIGURE 21 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 22 NOVARTIS AG: REGIONAL REVENUE
FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 26 PFIZER INC: KEY FINANCIALS
FIGURE 27 PFIZER INC: SEGMENTAL REVENUE
FIGURE 28 PFIZER INC: REGIONAL REVENUE
FIGURE 29 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 30 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 31 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 32 MERCK AND CO. INC.: KEY FINANCIALS
FIGURE 33 MERCK AND CO. INC.: SEGMENTAL REVENUE
FIGURE 34 MERCK AND CO. INC.: REGIONAL REVENUE
FIGURE 35 CIPLA LIMITED: KEY FINANCIALS
FIGURE 36 CIPLA LIMITED: SEGMENTAL REVENUE
FIGURE 37 CIPLA LIMITED: REGIONAL REVENUE
FIGURE 38 LUPIN LIMITED: KEY FINANCIALS
FIGURE 39 LUPIN LIMITED: SEGMENTAL REVENUE
FIGURE 40 LUPIN LIMITED: REGIONAL REVENUE
FIGURE 41 DR. REDDY'S LABORATORIES: KEY FINANCIALS
FIGURE 42 DR. REDDY'S LABORATORIES: SEGMENTAL REVENUE
FIGURE 43 DR. REDDY'S LABORATORIES: REGIONAL REVENUE
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE
FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE
FIGURE 47 RXFUNCTION, INC.: KEY FINANCIALS
FIGURE 48 RXFUNCTION, INC.: SEGMENTAL REVENUE
FIGURE 49 RXFUNCTION, INC.: REGIONAL REVENUE
Peripheral Neuropathy Market Segmentation
Peripheral Neuropathy Market Type Outlook (USD Billion, 2019-2030)
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Peripheral Neuropathy Market Treatment Outlook (USD Billion, 2019-2030)
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Peripheral Neuropathy Market End User Outlook (USD Billion, 2019-2030)
Hospitals and Clinics
Ambulatory Centers
Others
Peripheral Neuropathy Market Regional Outlook (USD Billion, 2019-2030)
North America Outlook (USD Billion, 2019-2030)
North America Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
North America Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
North America Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
US Outlook (USD Billion, 2019-2030)
US Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
US Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
US Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Canada Outlook (USD Billion, 2019-2030)
Canada Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Canada Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Canada Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Europe Outlook (USD Billion, 2019-2030)
Europe Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Europe Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Europe Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Germany Outlook (USD Billion, 2019-2030)
Germany Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Germany Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Germany Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
France Outlook (USD Billion, 2019-2030)
France Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
France Peripheral Neuropathy Market Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
France Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
UK Outlook (USD Billion, 2019-2030)
UK Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
UK Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
UK Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Italy Outlook (USD Billion, 2019-2030)
Italy Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Italy Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Italy Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Spain Outlook (USD Billion, 2019-2030)
Spain Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Spain Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Spain Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Rest Of Europe Outlook (USD Billion, 2019-2030)
Rest Of Europe Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Rest of Europe Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Rest of Europe Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Asia-Pacific Outlook (USD Billion, 2019-2030)
Asia-Pacific Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Asia-Pacific Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Asia-Pacific Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
China Outlook (USD Billion, 2019-2030)
China Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
China Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
China Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Japan Outlook (USD Billion, 2019-2030)
Japan Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Japan Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Japan Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
India Outlook (USD Billion, 2019-2030)
India Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
India Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
India Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Australia Outlook (USD Billion, 2019-2030)
Australia Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Australia Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Australia Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
South Korea Outlook (USD Billion, 2019-2030)
South Korea Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
South Korea Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
South Korea Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)
Rest of Asia-Pacific Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Rest of Asia-Pacific Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Rest of Asia-Pacific Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Rest of the World Outlook (USD Billion, 2019-2030)
Rest of the World Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Rest of the World Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Rest of the World Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Middle East Outlook (USD Billion, 2019-2030)
Middle East Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Middle East Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Middle East Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Africa Outlook (USD Billion, 2019-2030)
Africa Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Africa Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Africa Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Latin America Outlook (USD Billion, 2019-2030)
Latin America Peripheral Neuropathy Market by Type
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Latin America Peripheral Neuropathy Market by Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Latin America Peripheral Neuropathy Market by End User
Hospitals and Clinics
Ambulatory Centers
Others
Research Methodology on Peripheral Neuropathy Market
Abstract
This report presents a comprehensive research methodology for the Market Research Future (MRFR) report on Peripheral Neuropathy. It discusses the research objectives and approaches, data collection methods and selection criteria for data sources, and analytical methods used in the research. It also outlines the key assumptions and limitations that informed the research. The methodology enables MRFR to undertake analytical investigations into the causes and impacts of Peripheral Neuropathy on the market and patients. It further helps MRFR to produce high-quality, accurate reports that meet the needs of its customers and support informed decision-making.
Introduction
Peripheral Neuropathy (PN) is a medical condition resulting in damage to the peripheral nerves. It can cause a range of symptoms including numbness, tingling, burning, or painful sensations in the hands and feet, muscle weakness, muscle cramps and fatigue, loss of reflexes, and even cognitive impairment. It is typically caused by certain underlying conditions or diseases, like diabetes, traumatic injuries, exposure to certain drugs and toxins, and even genetic causes. PN affects over 20 million people in the US alone, and its incidence is projected to rise over the coming years as the population ages and diabetes prevalence increases. Treatment options for PN include medications, physical therapy, dietary changes and lifestyle modifications, and alternative and complementary therapies.
For this report, MRF examined the global peripheral neuropathy market and its drivers, restraints, and opportunities. It also explored existing and potential treatments, developments in diagnostics and therapeutics, current and emerging clinical trials, and top companies operating in the market. To support its analysis, MRFR used various primary and secondary resources, such as expert interviews, industry surveys, and public data sources.
Research Objectives
The objective of this study is to produce an exhaustive report on the global peripheral neuropathy market, including its drivers, restraints, and opportunities. The objectives of the study were the following:
Research Approaches Used
In this report, MRFR used a concurrent mixed methods design, which involved a combination of qualitative and quantitative research methods. This was employed to generate an accurate, comprehensive report on the global peripheral neuropathy market. MRFR used a range of primary and secondary sources to inform its analysis. This involved interviews with health professionals and experts in the field, industry surveys, and public data sources.
Data Collection Methods
MRFR employed a variety of data collection methods to obtain the necessary data for the report. These included expert interviews, industry surveys, and public data sources. MRF used a structured questionnaire to conduct the interviews, which included open-ended questions about the participants’ knowledge pertaining to the peripheral neuropathy market. Questions focused on various topics, such as their perceptions of the current market and their views on its potential future. Interviews were partially transcribed and then analyzed to look for common themes, which informed MRFR's analysis of the peripheral neuropathy market.
Secondly, MRFR undertook an industry survey to gain an understanding of the current industry landscape and available treatments for peripheral neuropathy. This survey is conducted online and respondents were asked about their experience with peripheral neuropathy, treatment preferences, and areas of unmet need.
Finally, MRFR accessed a range of public sources of data, such as studies, medical journals, patent documents, and clinical trials, to obtain the necessary information to inform the report.
Data Source Selection Criteria
In order to ensure that the data source for the report was of high quality, MRFR employed the following data source selection criteria. Sources of data were categorically assessed to ensure their relevance and accuracy. Sources were chosen based on the following criteria:
Analytical Methods Used
MRFR employed a range of analytical methods for the report, including qualitative data analysis, quantitative data analysis, and market modelling. For qualitative analysis, MRFR used content analysis to examine the expert interviews and industry survey responses to identify common themes and patterns. This enabled MRFR to develop meaningful insights into the views of experts and other market participants regarding the peripheral neuropathy market.
MRFR also employed quantitative analysis, based on the large amount of numerical data sourced. This involves descriptive statistics and data manipulation to look for trends and patterns in the data. Finally, MRFR used market modelling to develop a comprehensive view of the peripheral neuropathy market. This enabled MRFR to create forecasts and long-term projections for the market and its segments.
Conclusions
This report presents a comprehensive research methodology for the Market Research Future (MRF) report on Peripheral Neuropathy. It outlines the research objectives and approaches, data collection methods and selection criteria for data sources, and analytical methods used in the research. It also outlines the key assumptions and limitations that informed the research. The methodology enables MRFR to undertake analytical investigations into the causes and impacts of Peripheral Neuropathy on the market and patients. It further helps MRFR to produce high-quality, accurate reports that meet the needs of its customers and support informed decision-making along with the forecast from 2023 to 2030.